National Association of Testing Authorities, Australia
Scope of Accreditation
Sullivan Nicolaides Pathology
Sonic Healthcare Pty Ltd
Site
Bowen Hills Laboratory
Accreditation No.
1964
Site No.
23038
Date of Accreditation
27 Aug 1985
Contact
Ms Fiona Jenkins P: +61 (07) 33778367
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Biochemistry Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of calculus | Biliary calculi | Ammonium; Brushite; Calcium; Calcium bilirubinate; Calcium oxalate dihydrate (weddelite); Cysteine; Hydrated calcium oxalate (whewellite); Hydroxylapatite (hydroxyapatite); Magnesium; Oxalate; Phosphate; Triple phosphate - Struvite; Uric acid; Whitlockite |
| Calculi | Cholesterol | |
| Renal calculi | Ammonium; Brushite; Calcium; Calcium bilirubinate; Calcium oxalate dihydrate (weddelite); Cysteine; Hydrated calcium oxalate (whewellite); Hydroxylapatite (hydroxyapatite); Magnesium; Oxalate; Phosphate; Triple phosphate - Struvite; Uric acid; Whitlockite | |
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Plasma | Benzodiazepines; Clobazam; Clonazepam; Diazepam; Norclobazam; Nordiazepam |
| Serum | 6:2 Fluorotelomer sulfonate (6:2 FTS); Perfluorobutane sulfonate (PFBS); Perfluorodecanoic acid (PFDA); Perfluoroheptanoic acid (PFHpA); Perfluorohexane sulfonate (PFHxS); Perfluorohexanoic acid (PFHxA); Perfluorononanoic acid (PFNA); Perfluorooctane sulfonic acid (PFOS); Perfluorooctanoic acid (PFOA) | |
| Alcohol | ||
| Chemical pathology - Biogenic amines | Blood | Serotonin |
| Histamine | ||
| Plasma | Metanephrine; Methoxytyramine; Normetanephrine | |
| Urine | 5-Hydroxyindoleacetic acid (5-HIAA); Homovanillic acid (HVA); Vanillylmandelic acid (VMA) | |
| Adrenaline; Catecholamines; Dopamine; Metanephrine; Noradrenaline; Normetanephrine | ||
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | Tacrolimus |
| Cyclosporin | ||
| Plasma | Perhexiline | |
| Methotrexate | ||
| Amitriptyline; Clomipramine; Desipramine; Dothiepin (dosulepin); Doxepin; Imipramine; Levetiracetam; Norclomipramine; Nordoxepin; Nortriptyline; Oxcarbazepine; Trimipramine | ||
| Serum | Clozapine; Norclozapine | |
| Lithium; Paracetamol (acetaminophen); Tobramycin | ||
| Carbamazepine; Digoxin; Gentamicin (cidomycin, septopal, genticyn, garamycin); Phenobarbitone; Phenytoin (dilantin); Theophylline; Valproate (valproic acid, epilim); Vancomycin | ||
| Amiodarone; Flecainide; Lamotrigine; Oxcarbazepine; Primidone | ||
| Chemical pathology - Detection and/or quantitation of tumour markers | Plasma | Parathyroid hormone-related peptide (PTHrP) |
| Serum | Thyroglobulin | |
| Carcinoembryonic antigen (CEA); Human epididymal protein 4 | ||
| Human chorionic gonadotropin (hCG) | ||
| Chromogranin A - Gen I; Chromogranin A - Gen II | ||
| CA19-9 antigen (CA19-9); CA72-4 antigen (CA72-4) | ||
| Prostate specific antigen (PSA); Prostate specific antigen (PSA) fractions and derived index | ||
| CA125 antigen (CA125); CA15-3 antigen (CA15-3); Prostate specific antigen (PSA); Prostate specific antigen (PSA) - Free; α-Fetoprotein (AFP) | ||
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Parathyroid hormone (PTH) |
| Parathyroid hormone-related peptide (PTHrP) | ||
| Renin | ||
| Glucagon; Vasoactive intestinal peptide (VIP) | ||
| Cortisol | ||
| Plasma; Serum | Copeptin | |
| Serum | Dehydroepiandrosterone sulfate (DHEAS); Sex hormone binding globulin (SHBG); Testosterone; Testosterone - Free; Testosterone - Total | |
| 17α-Hydroxyprogesterone | ||
| Anti-Mullerian hormone (AMH) | ||
| C-peptide; Calcitonin; Erythropoietin (EPO); Gastrin; Growth hormone | ||
| Cortisol; Follicle stimulating hormone (FSH); Insulin; Luteinising hormone (LH); Oestradiol; Progesterone; Prolactin | ||
| Insulin-like growth factor-binding protein 3 (IGF-BP3) | ||
| Inhibin B (Inh-B) | ||
| Aldosterone; Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| Macroprolactin | ||
| Androstenedione | ||
| Adrenocorticotropic hormone (ACTH) | ||
| Aldosterone | ||
| Leptin; Pancreatic polypeptide (PP); Proinsulin | ||
| Urine | Cortisol; Cortisol - Free | |
| Aldosterone | ||
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Serum | Fructosamine | |
| 1,5-Anhydroglucitol (AHG) | ||
| Chemical pathology - Dynamic tests | Sweat | Sweat chloride; Sweat sodium; Sweat tests |
| Chemical pathology - Further investigation of cardiac function | Plasma; Serum | Troponin I |
| Serum | N-Terminal-pro b-type natriuretic peptide (NT-proBNP); Troponin T | |
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Serum | Apolipoprotein A; Apolipoprotein B; LDL - Small dense (sdLDL) |
| Lipoprotein a | ||
| Chemical pathology - Further investigation of renal and/or hepatic function | Serum | Hyaluronic acid |
| Bile acids - Quantitative | ||
| Alkaline phosphatase (ALP) isoenzymes; Lactate dehydrogenase (LDH) isoenzymes | ||
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Cerebrospinal fluid (CSF) | Xanthochromia |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Ascitic fluid; Drainage fluid; Peritoneal fluid; Pleural fluid | Albumin; Amylase; Bilirubin - Total; Calcium - Corrected for albumin; Chloride; Cholesterol - Total; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea |
| Blood | Acetylcholinesterase (RCAC) | |
| Cerebrospinal fluid (CSF) | Chloride; Glucose; Lactate; Protein - Total | |
| Cyst fluid | Albumin; Amylase; C-reactive protein (CRP); Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Protein - Total; Urate; Urea | |
| Drainage fluid; Pleural fluid | Albumin; Bicarbonate; Bilirubin - Direct; Bilirubin - Total; C-reactive protein (CRP); Calcium - Corrected for albumin; Chloride; Cholesterol - Total; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea | |
| Plasma | Lactate | |
| Ammonia | ||
| Serum | Cholesterol - LDL | |
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Corrected for albumin; Chloride; Cholesterol - HDL; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | ||
| Cholinesterase | ||
| Dibucaine (cinchocaine); Lactate | ||
| Procollagen type 3 N-terminal propeptide (P3NP) | ||
| Angiotensin converting enzyme (ACE) | ||
| Serum; Urine | Osmolality | |
| Synovial fluid | Albumin; Bicarbonate; Bilirubin - Direct; Bilirubin - Total; C-reactive protein (CRP); Chloride; Cholesterol - Total; Glucose; Lactate dehydrogenase (LDH); Potassium; Protein - Total; Sodium; Triglycerides | |
| Urine | Albumin; Albumin/creatinine ratio (ACR); Amylase; Calcium - Corrected for albumin; Calcium - Total; Chloride; Creatinine; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea; Uric acid | |
| pH | ||
| Albumin; Ammonia | ||
| Chemical pathology - Investigation for folate deficiency | Blood | Red blood cell folate |
| Blood; Serum | Folate | |
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C14; Urease |
| Chemical pathology - Investigation of functional intestinal disorders | Breath | Hydrogen/methane |
| Chemical pathology - Investigation of malabsorption | Breath | Breath hydrogen |
| Faeces | Faecal fat | |
| Chemical pathology - Investigation of malabsorption - Quantitation of solid tissue enzymes | Intestinal tissue | Alkaline phosphatase; Glucose; Lactase; Maltase; Sucrase |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Amniotic fluid; Serum | α-Fetoprotein (AFP) |
| Serum | Free β-human chorionic gonadotropin (free β-hCG); Placental growth factor (PGF, PLGF); Pregnancy associated plasma protein A (PAPP-A); α-Fetoprotein (AFP) | |
| Chemical pathology - Investigation of porphyria | Blood; Plasma cells; Urine | Haemoglobinuria; Porphobilinogen (PBG); Porphyrins - Total; Protoporphyrin; Uroporphyrin; δ-Aminolevulinic acid (δ-ALA) |
| Chemical pathology - Iron studies | Serum | Ferritin |
| Iron; Transferrin | ||
| Chemical pathology - Markers of bone metabolism | Plasma | c-Telopeptide (CTx) |
| Serum | Osteocalcin; Procollagen type 1 N-terminal propeptide (P1NP) | |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bilirubin - Total; Calcium - Ionised; Calcium - Ionised (pH corrected); Carboxyhaemoglobin; Chloride; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Mixed venous oxygen content (CvO2); Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Sodium; p50; pH |
| Serum | Calcium - Ionised; Calcium - Ionised (pH corrected); pH | |
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Serum | Homocysteine |
| β-Hydroxybutyrate | ||
| Urine | Citrate | |
| Oxalate | ||
| Chemical pathology - Quantitation of vitamin B markers | Serum | Holotranscobalamin (active vitamin B12) |
| Methylmalonic acid (MMA) | ||
| Chemical pathology - Quantitation of vitamins | Blood | Pyridoxine (vitamin B6, pyridoxal, pyridoxamine); Riboflavin (vitamin B2); Thiamine (vitamin B1) |
| Serum | Carotenoids | |
| 1,25-Dihydroxyvitamin D; 25-Hydroxyvitamin D | ||
| Cobalamin (vitamin B12) | ||
| Ascorbic acid (vitamin C); Retinol (vitamin A); Tocopherol (vitamin E) | ||
| Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulation immunoglobulins |
| Serum | Triiodothyronine (T3) - Reverse | |
| Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free | ||
| Chemical pathology - Trace element analysis | Blood; Plasma | Aluminium; Arsenic; Cadmium; Chromium; Cobalt; Copper; Iodine; Lead; Magnesium; Manganese; Mercury; Nickel; Selenium; Silver; Strontium; Zinc |
| Hair | Aluminium; Arsenic; Barium; Bismuth; Cadmium; Cobalt; Copper; Lead; Manganese; Mercury; Nickel; Selenium; Thallium; Uranium; Vanadium; Zinc | |
| Plasma | Copper; Selenium; Zinc | |
| Urine | Arsenic speciation | |
| Aluminium; Arsenic; Cadmium; Chromium; Cobalt; Copper; Iodine; Lead; Manganese; Mercury; Nickel; Selenium; Strontium; Zinc | ||
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-acetylcholine receptor antibodies (AChR); Anti-double stranded DNA antibodies (dsDNA); Anti-insulin antibodies |
| Rheumatoid factor | ||
| Anti-cyclic citrullinated peptide antibodies (CCP); Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Anti-thyroid receptor antibodies | ||
| Immunopathology - Quantitation of complement proteins | Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative and/or qualitative investigation of glycoproteins | Plasma; Serum | TIMP metallopeptidase inhibitor 1 (TIMP1) |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Serum | Human chorionic gonadotropin (hCG) |
| Urine | Human chorionic gonadotropin (hCG) | |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Urine | Urobilinogen |
| Glucose; Ketones | ||
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Hepatitis C virus antibody (anti-HCV) - IgG |
| Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - IgG; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis C virus (HCV); Human T-lymphotropic virus type I/II (HTLV-I/II) antibody; Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies; Human immunodeficiency virus type 1/2 (HIV-1/2) antigen; Rubella IgG antibody |
Blood Bank Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Investigation of haemolysis | Blood | Cold agglutinins |
| Immunohaematology - Blood group antibody detection | Blood | Duffy system; Kell system; M and N factors; Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Antibody elution |
| Direct antiglobulin test (DAT, direct Coombs test) | ||
| Antibody titration | ||
| Other blood group antibodies; Red blood cell phenotyping; Rh | ||
| Antibody titration | ||
| Plasma | Other blood group antibodies | |
| Immunohaematology - Investigation of blood transfusion reactions | Blood; Blood products | Antibodies; Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Blood products | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products | Issue and release of blood and blood products for transfusion |
Cytogenetics Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in-situ hybridisation techniques | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant; Paraffin embedded tissue | Cytogenetic analysis and reporting |
| Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Other tissues - Malignant; Other tissues - Non-malignant | Cytogenetic analysis and reporting |
| Amniotic fluid; Blood; Buccal swabs; Chorionic villus tissue; Other tissues - Non-malignant; Products of conception (POC) | Constitutional genetic abnormalities | |
| Blood; Bone marrow; Other tissues - Malignant | Pathogenic copy number changes | |
| Molecular genetics - DNA extraction | Blood | DNA storage for future analyses |
Cytopathology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical tissue | Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Vaginal tissue | Cytological examination; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Cerebrospinal fluid (CSF); Other body fluids; Sputum; Urine; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Anus smears; Lip smears; Mouth smears; Nipple discharge; Nose smears; Skin smears | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix; Liquid based cytology specimens from vaginal vault | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
| Self-collected vaginal swabs | Human papilloma virus (HPV) |
Faecal Occult Blood Testing Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection and/or quantitation of tumour markers - Testing for the National Bowel Cancer Screening Program | Faeces | Blood |
Haematology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Bone marrow examination | Bone marrow; Trephine | Examination of aspirated material |
| Haematology - Diagnosis of thalassemia | Blood | Examination of haemoglobin H (HbH); Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation; Haemoglobin H (HbH) inclusions |
| Haematology - Examination of blood films by special staining | Blood | Heinz bodies |
| Malaria | ||
| Haematology - Full blood examination | Blood | Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Platelet count; Red blood cell index or indices |
| Morphology | ||
| Differential number; Reticulocytes | ||
| Morphology | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
| Plasma | Activated partial thromboplastin time (APTT); Activated protein C (APC) resistance; Anti-Xa - Apixaban; Anti-Xa - Rivaroxaban; Anti-thrombin III; D-dimer; Echis test; Factor II; Factor IX; Factor V; Factor VII; Factor VIIIc; Factor VIIIc inhibitor; Factor X; Factor XI; Factor XII; Factor XIII; Fibrinogen; Fletcher factor; Heparin assay; International normalised ratio (INR); Lupus anticoagulant; Platelet aggregation; Protein C and protein S; Prothrombin time (PT); Reptilase time; Thrombin time (TT); Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | |
| Heparin induced thrombotic thrombocytopenia (HITT) | ||
| Anti-IIa - Dabigatran | ||
| Von Willebrand collagen binding assay | ||
| Activated partial thromboplastin time (APTT); Fibrinogen; International normalised ratio (INR); Prothrombin time (PT) | ||
| Activated partial thromboplastin time (APTT); Anti-thrombin III; D-dimer; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Protein C; Protein S; Prothrombin time (PT); Thrombin time (TT); Von Willebrand factor (vWF) | ||
| Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Haemoglobin instability; Other abnormal haemoglobins |
| Haemoglobin S (HbS) - Presence | ||
| Other abnormal haemoglobins | ||
| Haematology - Investigation of haemolysis | Urine | Haemosiderin |
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Blood | Plasmodium falciparum; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
| Babesia spp. | ||
| Microfilaria |
Histopathology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Examination of biopsy material by electron microscopyReporting only | Gluteraldehyde tissue | Review and reporting of biopsy material to identify or exclude ultra-structural morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in-situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue; Tissue imprint | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Fixed cytological smears; Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of antigenic targets - Various |
Immunology/Serology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Serum | Adalimumab; Infliximab; Ustekinumab; Vedolizumab |
| Chemical pathology - Detection and/or quantitation of tumour markers | Serum | β2-Microglobulin (B2M) |
| Chemical pathology - Further investigation of cardiac function | Serum | Creatine kinase (CK) isoenzymes |
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Serum | Apolipoprotein A |
| Chemical pathology - Further investigation of renal and/or hepatic function | Serum | Caeruloplasmin |
| Tryptase | ||
| α1-Antitrypsin phenotype | ||
| Alkaline phosphatase (ALP) isoenzymes; Lactate dehydrogenase (LDH) isoenzymes | ||
| Prealbumin; α1-Antitrypsin | ||
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Serum; Urine | Myoglobin |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Cerebrospinal fluid (CSF) | Albumin |
| Serum | Carbohydrate deficient transferrin | |
| C1 esterase inhibitor functional | ||
| C1 esterase inhibitor; Soluble transferrin receptor (sTFR) | ||
| Carbohydrate deficient transferrin | ||
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Presence of anti-D; Presence of foetal red blood cells |
| Haematology - Investigation of haemolysis | Serum | Haptoglobins |
| Immunohaematology - Identification of granulocyte antibodies | Blood products | Granulocyte specific antibodies |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood | B-cell; Eosin-5-maleimide; Lymphocyte surface markers; Paroxysmal nocturnal haemoglobinuria (PNH) surface markers; Platelet antibodies |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma; Serum | Anti-phospholipase A2 receptor antibodies (PLA2R) |
| Phosphatidylserine/prothrombin complex (PS/PT) IgG antibodies | ||
| Serum | Anti-nuclear antibodies (ANA) | |
| Anti-double stranded DNA antibodies (dsDNA) | ||
| Anti-adrenal cortex antibodies; Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-neuronal antibodies; Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-ovarian antibodies (AOA); Anti-smooth muscle antibodies (SMA) | ||
| Anti-GD1b IgG antibody; Anti-GQ1b IgG antibody; Anti-ganglioside antibodies | ||
| Anti-IgLON5 antibodies | ||
| Anti-skin antibodies | ||
| Anti-neuronal antibodies | ||
| Anti-Saccharomyces cerevisiae antibodies (ASCA); Anti-cardiolipin antibodies (ACA); Anti-double stranded DNA antibodies (dsDNA); Anti-extractable nuclear antigen antibodies (ENA); Anti-gastric parietal cell antibodies (GPC/PCA); Anti-gliadin antibodies (AGA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-intrinsic factor antibodies (IF); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG); Anti-β2-glycoprotein-I antibodies | ||
| Anti-EJ antibodies; Anti-Jo-1 antibodies; Anti-Ku antibodies; Anti-Mi-2 antibodies; Anti-NXP2 antibodies; Anti-OJ antibodies; Anti-PL-12 antibodies; Anti-PL-7 antibodies; Anti-Pm/Scl-100 antibodies; Anti-Pm/Scl-75 antibodies; Anti-Ro-52 antibodies; Anti-SAE1 antibodies; Anti-melanoma differentiation associated gene 5 antibodies (MDA5); Anti-signal recognition particle antibodies (SRP); Anti-transcription intermediary factor antibodies (TIF1) | ||
| Anti-islet tyrosine phosphatase2 (IA2) antibodies; Anti-zinc transporter protein 8 antibodies (ZNT8) | ||
| Anti-muscle specific kinase antibodies (MuSK) | ||
| Anti-adalimumab antibodies; Anti-infliximab antibodies | ||
| Anti-glutamate receptor antibodies (AMPA/NMDA); Anti-neuromyelitis optica antibodies (NMO) | ||
| Dermatology profile - BP180, BP230, desmoglein 1, desmoglein 3, envoplakin and collagen type VII | ||
| Anti-glutamic acid decarboxylase antibodies (GAD) | ||
| Anti-myelin oligodendrocyte glycoprotein antibodies (MOG) | ||
| Anti-extractable nuclear antigen antibodies (ENA) | ||
| Anti-myelin associated glycoprotein antibodies (MAG) | ||
| Anti-HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase) | ||
| Anti-skeletal muscle antibodies | ||
| Anti-endomysial antibodies (EMA) | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential component testing (purified native and/or recombinant allergens)) | Serum | Ara h2 - Peanut; Omega-5-gliadin - Wheat; Ovomucoid - Egg |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicilloyl group; Ampicilloyl group; Chlorhexidine; Morphine; Penicilloyl G; Penicilloyl V |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Cat epithelium; Chicken feathers; Cow dander; Dog dander; Feather mix; Guinea pig epithelium; Horse dander; Sheep dander; Sheep epithelium |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg white; Egg yolk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Codfish; Crab; Lobster; Oyster; Salmon; Seafood mix; Shrimp; Squid; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Apple; Avocado; Banana; Fruit mix; Garlic; Kiwi; Mango; Onion; Orange citrus; Pineapple; Potato; Strawberry; Tomato |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Lamb; Pork |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Casein; Cheese - Cheddar type; Milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Cacao; Chocolate; Coffee; Mushroom; Staple food mix; Yeasts |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Cashew nut; Cereal mix; Chick pea; Coconut; Corn; Gluten; Hazelnut; Macadamia nut; Nut panel; Oat; Peanut; Pecan nut; Pinenut; Pistachio; Rice; Rye; Sesame seed; Soy bean; Walnut |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Bermuda grass; Johnson grass; Paspalum grass; Rye grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | German cockroach |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Aspergillus fumigatus |
| Alternaria alternata; Aspergillus fumigatus; Cladosporium herbarum; Penicillium chrysogenum (formerly Penicillium notatum); Mould mix | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Blomia tropicalis house dust mite; Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Latex |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Eucalyptus; Melaleuca; Silver birch; Tree mix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Common wasp (yellow jacket) venom; Honey bee venom; Paper wasp venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Common ragweed; Weed mix |
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cells | Blood; Haemopoietic progenitor cells | Enumeration of CD34+ cells |
| Immunopathology - Quantitation of complement proteins | Serum | Total complement activation |
| C1q; C2 | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Cerebrospinal fluid (CSF) | Oligoclonal bands |
| Faeces | Calprotectin 2 | |
| Elastase | ||
| α1-Antitrypsin | ||
| Other body fluids | β-Trace protein (β-TP) | |
| Plasma | Cryofibrinogen | |
| Serum | Cryoglobulins | |
| Anti-daratumumab | ||
| Detection and quantitation of free kappa and free lambda light chains; Immunoglobulin A (IgA) - Kappa; Immunoglobulin A (IgA) - Lambda; Immunoglobulin G (IgG) - Kappa; Immunoglobulin G (IgG) - Lambda; Immunoglobulin M (IgM) - Kappa; Immunoglobulin M (IgM) - Lambda; Oligoclonal bands | ||
| Albumin; Characterisation of paraproteins; Detection and amount of paraproteins; Oligoclonal bands; α1-Globulin; α2-Globulin; β-Globulin; β1-Globulin; β2-Globulin; γ-Globulin | ||
| Detection and quantitation of free kappa and free lambda light chains | ||
| Urine | Characterisation of paraproteins; Detection and amount of paraproteins; Oligoclonal bands | |
| Detection and quantitation of free kappa and free lambda light chains; Immunoglobulin A (IgA) - Kappa; Immunoglobulin A (IgA) - Lambda; Immunoglobulin G (IgG) - Kappa; Immunoglobulin G (IgG) - Lambda; Immunoglobulin M (IgM) - Kappa; Immunoglobulin M (IgM) - Lambda; Oligoclonal bands | ||
| Immunopathology - Quantitative investigation and/or assessment of neutrophils | Blood | Dihydrorhodamine 123; Quantitation of neutrophil function |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Cerebrospinal fluid (CSF) | Total immunoglobulin G |
| Serum | Immunoglobulin subclasses; Total immunoglobulin A; Total immunoglobulin D; Total immunoglobulin G; Total immunoglobulin M | |
| Total immunoglobulin E | ||
| Immunopathology - Single HLA antigen typing | Blood | HLA-B27 |
| Infertility and pregnancy tests including assisted reproductive technology - Investigation of sperm | Semen | Sperm antibodies |
| Microbiology - Mycobacteriology - Tests for cell mediated immunity | Blood | Latent tuberculosis |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Bronchoalveolar lavage; Serum | Aspergillus galactomannan antigen |
| Cerebrospinal fluid (CSF); Serum | Cryptococcus spp. | |
| Borrelia burgdorferi IgG | ||
| Faeces | Helicobacter pylori | |
| Plasma; Serum | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | |
| Zika virus IgG antibody; Zika virus IgM antibody | ||
| Serum | Corynebacterium diphtheriae spp. antibody | |
| Campylobacter jejuni; Coxiella burnetii (Q-fever) phase 1 total antibody; Coxiella burnetii (Q-fever) phase 2 total antibody; Influenza A virus; Influenza B virus; Varicella zoster virus (VZV); Yersinia spp. | ||
| Measles IgM antibody | ||
| Toxoplasma spp. IgG antibody; Toxoplasma spp. IgM antibody; Toxoplasma avidity | ||
| Coxiella burnetii (Q-fever) IgA phase 1 antibody; Coxiella burnetii (Q-fever) IgA phase 2 antibody; Coxiella burnetii (Q-fever) IgG phase 1 antibody; Coxiella burnetii (Q-fever) IgG phase 2 antibody; Coxiella burnetii (Q-fever) IgM phase 1 antibody; Coxiella burnetii (Q-fever) IgM phase 2 antibody | ||
| Anti-streptolysin O (ASOT) | ||
| Chikungunya virus IgG antibody; Chikungunya virus IgM antibody | ||
| Legionella longbeachae antibody; Legionella pneumophila total antibody | ||
| Syphilis Treponema pallidum antibody | ||
| Syphilis Treponema pallidum IgG antibody | ||
| Helicobacter pylori IgG antibody | ||
| Bartonella spp. IgG antibody | ||
| Chlamydial spp. IgG antibody | ||
| Histoplasma spp.; Mycelium | ||
| Barmah forest virus IgG antibody; Barmah forest virus IgM antibody; Bordetella pertussis IgG; Ross River virus IgG antibody; Ross River virus IgM antibody | ||
| Dengue virus IgG antibody; Dengue virus IgM antibody; Dengue virus NS1 antigen | ||
| Hydatid antibody | ||
| Dengue virus IgG antibody; Dengue virus IgM antibody | ||
| Rubella IgM antibody | ||
| Cytomegalovirus (CMV) IgG avidity; Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Epstein-Barr virus IgG antibody; Epstein-Barr virus IgM antibody; Epstein-Barr virus nuclear antigen; Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Measles IgG antibody; Measles IgM antibody; Mumps virus IgG antibody; Mumps virus IgM antibody; Mycoplasma pneumoniae IgG antibody; Mycoplasma pneumoniae IgM antibody; Parvovirus IgG antibody; Parvovirus IgM antibody; Rubella IgM antibody; Varicella zoster virus (VZV) IgG antibody; Varicella zoster virus IgM antibody | ||
| Dengue virus NS1 antigen | ||
| Leptospira IgM antibody | ||
| Aspergillus spp. total antibody; Micropolyspora faeni IgG antibody; Thermoactinom vulgars specific antigens; Anti-Aspergillus IgG; Avian precipitins (bird fancier's disease) | ||
| Tetanus IgG antibody | ||
| Entamoeba histolytica | ||
| Hepatitis E virus (HEV) IgG; Hepatitis E virus (HEV) IgM | ||
| Schistosoma mansoni IgG antibody | ||
| Strongyloides spp. antibody | ||
| Haemophilus influenzae type B IgG antibody | ||
| Brucella spp.; Brucella IgG antibody; Brucella IgM antibody | ||
| Streptococcus pneumoniae IgG antibody | ||
| Hepatitis D virus antibody (anti-HDV) - IgG | ||
| Rabies virus | ||
| Coxiella burnetii (Q-fever) IgG phase 2 antibody; Coxiella burnetii (Q-fever) IgM phase 2 antibody | ||
| Parvovirus IgM antibody | ||
| Rickettsia spp. IgG antibody |
Microbiology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis (other than post vasectomy) | Semen | Agglutination; Aggregation; Colour; Differential number; Leucocytes (white blood cells, WBC); Morphology; Motility; Sperm number; Viscosity; Vitality; Volume; pH |
| Morphology; Motility; Sperm number; Vitality | ||
| Viscosity; Volume | ||
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis for post vasectomy and/or examination of cervical mucus | Semen | Presence of spermatozoa |
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Aspirates; Cerebrospinal fluid (CSF); Synovial fluid | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) |
| Aspirates; Isolates | Antibiotic susceptibility; Cultured pathogens identification; Pathogenic identification and antibiotic susceptibility | |
| Antibiotic susceptibility | ||
| Cultured pathogens identification | ||
| Bacterial isolates | Pathogenic identification and antibiotic susceptibility | |
| Pathogenic identification | ||
| Blood | Cultured pathogens identification | |
| Cerebrospinal fluid (CSF); Urine | Streptococcus pneumoniae antigen | |
| Ear swabs; Eye swabs; Genital swabs; Nasal swabs; Skin swabs; Throat swabs | Bacteria; Epithelial cells; Leucocytes (white blood cells, WBC) | |
| Fluids; General swabs; Isolates; Sputum; Tissues; Urine | Cultured pathogens identification | |
| Gastric biopsy | Helicobacter pylori | |
| Genital swabs | Streptococcus group B screening | |
| Urine | Legionella antigen | |
| Antigenic detection; Bacteria; Blood; Casts; Crystals; Eosinophils; Epithelial cells; Erythrocytes (red blood cells, RBC); Glucose; Haemoglobin (Hb); Ketones; Leucocytes (white blood cells, WBC); Pathogenic microorganisms; Proteins; Specific gravity; Sugar; Urobilinogen; pH | ||
| Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Specific gravity | ||
| Microbiology - Bacteriology - Detection of pathogenic bacteria for epidemiological infection control surveillance | Axilla swabs; Faeces; Groin swabs; Nasal swabs; Rectal swabs; Wounds | Extended spectrum beta-lactamases (ESBL); Methicillin resistant Staphylococcus aureus (MRSA); Vancomycin resistant Enterococci (VRE) |
| Microbiology - Environmental investigations and/or infection control | Gastrointestinal endoscopes | Bacterial growth - Sterility |
| Mycobacteria identification | ||
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Sediments; Sputum | Mycobacterium tuberculosis; Mycobacterium rifampicin resistance rpoB |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Bronchial washings; Bronchoalveolar lavage; Other body fluids; Sputum; Tissues; Urine | Mycobacteria identification |
| Cerebrospinal fluid (CSF); General swabs; Other body fluids; Respiratory specimens; Sputum; Tissues; Urine | Mycobacteria identification | |
| Cerebrospinal fluid (CSF); Other body fluids; Respiratory specimens; Sputum; Urine | Mycobacteria detection | |
| Other body fluids; Sputum | Mycobacteria identification | |
| Microbiology - Mycology - Detection of dermatophytes and other fungi causing cutaneous disease | Skin scrapings | Dermatophyte identification |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Skin scrapings | Fungi identification |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
| Microbiology - Virology - Detection of pathogenic viruses | Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Respiratory swabs and/or washings | Influenza A virus; Influenza B virus |
| Respiratory syncytial virus (RSV) |
Molecular Pathology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Aspirates; Bronchial washings; Bronchoalveolar lavage; Dry swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Throat swabs | Bordetella pertussis |
| Aspirates; Dry swabs; Nasopharyngeal aspirate; Paraffin embedded tissue; Tissues | Bartonella henselae | |
| Aspirates; Faeces | Aeromonas spp.; Campylobacter spp.; Escherichia coli - Enteroinvasive (EIEC); Salmonella spp.; Shigella spp.; Yersinia enterocolitica | |
| Bacterial isolates | MecA gene; Van A/B | |
| Carbapenem resistant Enterobacteriaceae (CRE) | ||
| Bacterial isolates; Cervical specimen; Dry swabs; Liquid based cytology specimens; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Bacterial isolates; Cervical specimen; General swabs; Liquid based cytology specimens; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Bacterial isolates; Faeces | Escherichia coli virulence factors | |
| Blood; Dry swabs; Faeces; Paraffin embedded tissue; Tissues | Tropheryma whipellii | |
| Bronchial swabs; Bronchial washings; Bronchoalveolar lavage; Eye swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs; Tonsil swabs | Mycoplasma pneumoniae | |
| DNA extracts | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Eye swabs; Genital swabs; Liquid based cytology specimens; Rectal swabs; Semen; Urine | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Faeces | Clostridioides difficile | |
| Fluids; General swabs; Paraffin embedded tissue; Tissues | Haemophilus ducreyi; Treponema pallidum | |
| Formalin-fixed paraffin-embedded (FFPE) tissues; Tissues | Helicobacter pylori | |
| Genital swabs; Liquid based cytology specimens; Rectal swabs; Throat swabs; Urine | Mycoplasma genitalium | |
| Serum | Leptospira spp. | |
| Serum; Tissues | Coxiella spp. | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (fungi) | Bronchial washings; Bronchoalveolar lavage; Nasopharyngeal aspirate; Sputum | Pneumocystis jirovecii |
| Hair; Nails; Skin scrapings | Dermatophyte identification; Fungi identification; Yeasts identification | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | General swabs; Paraffin embedded tissue; Tissues | Mycobacterium ulcerans |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Cerebrospinal fluid (CSF); Eye swabs; General swabs; Tissues | Acanthamoeba spp.; Balamuthia mandrillaris; Naegleria fowleri |
| Cervical specimen; General swabs; Genital swabs; Liquid based cytology specimens; Urine | Trichomonas vaginalis | |
| Faeces; Liver aspirate | Blastocystis hominis; Cryptosporidium spp.; Dientamoeba fragilis; Entamoeba histolytica; Giardia intestinalis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Aspirates; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Dry swabs; Eye swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs | Adenovirus; Enterovirus; Parainfluenza virus type 1/2/3/4 |
| Blood; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; General swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Tissues; Urine | Cytomegalovirus (CMV) | |
| Bronchial washings; General swabs; Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal swabs; Sputum; Throat swabs | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus; Respiratory syncytial virus (RSV) A/B; Rhinovirus; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Cerebrospinal fluid (CSF); General swabs; Tissues | Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Varicella zoster virus (VZV) | |
| Faeces; Vomitus | Adenovirus F40; Adenovirus F41; Astrovirus; Norovirus G1; Norovirus G2; Rotavirus; Sapovirus | |
| General swabs; Nasal swabs; Nasopharyngeal and throat swab; Throat swabs | Influenza A virus; Influenza B virus; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Liquid based cytology specimens | Human papilloma virus (HPV) | |
| Nasal swabs; Nasopharyngeal swabs | Influenza A virus; Influenza B virus; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasopharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) A/B; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Plasma; Serum | Hepatitis C virus (HCV) viral RNA | |
| Respiratory swabs; Urine | Measles virus | |
| Serum | Hepatitis C virus (HCV) genotypes 1-6 and subtypes | |
| Microbiology - Molecular biology - Microbial DNA and/or RNA extraction | Bacterial isolates; Blood; Bronchial swabs; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Fluids; Genital swabs; Liquid based cytology specimens; Liver aspirate; Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal aspirate; Nasopharyngeal swabs; Paraffin embedded tissue; Rectal swabs; Semen; Serum; Sputum; Throat swabs; Tissues; Urine | DNA storage for future analyses; Purified PCR product; Viable DNA; Viable DNA for sequencing |
| Blood; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Fluids; Formalin-fixed paraffin-embedded (FFPE) tissues; Genital swabs; Liquid based cytology specimens; Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal aspirate; Nasopharyngeal swabs; Paraffin embedded tissue; Rectal swabs; Serum; Sputum; Throat swabs; Tissues; Urine | DNA storage for future analyses; Purified PCR product; Viable DNA; Viable DNA for sequencing | |
| Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Fluids; Genital swabs; Liquid based cytology specimens; Nasal swabs; Nasopharyngeal and throat swab; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs; Urine | DNA storage for future analyses; Purified PCR product; Viable DNA; Viable DNA for sequencing | |
| Microbiology - Molecular biology - Quantitation of microbial nucleic acids | Plasma | Cytomegalovirus (CMV) viral load |
| Human immunodeficiency virus (HIV) RNA viral load | ||
| Plasma; Serum | Hepatitis B virus (HBV) viral load; Hepatitis C virus (HCV) viral load | |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | Methylenetetrahydrofolate reductase (MTHFR) |
| Factor V Leiden; Prothrombin variant | ||
| Hereditary haemochromatosis | ||
| Apolipoprotein E genotyping | ||
| Molecular genetics - DNA extraction | Blood; Bone marrow; Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues | DNA storage for future analyses; Purified PCR product; Viable DNA; Viable DNA for sequencing |
| Molecular genetics - DNA sequencing | Extracted DNA | Sequenced DNA utilising massively parallel sequencing technologies |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood | Quantitative calculation of p210 positive BCR::ABL1 transcripts |
| Blood; Blood aspirate; Formalin-fixed paraffin-embedded (FFPE) tissues | Lymphocyte DNA gene rearrangements | |
| Blood; Bone marrow | JAK2 V617F mutation | |
| Myeloproliferative leukaemia virus oncogene (MPL) | ||
| Calreticulin | ||
| Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues | BRAF mutation analysis | |
| Formalin-fixed paraffin-embedded (FFPE) tissues | KRAS mutation analysis | |
| EGFR mutation analysis; Gene fusion - Solid Tumour; KRAS mutation analysis; NRAS-BRAF mutation analysis | ||
| Copy number variation (CNV); MDM2 | ||
| MGMT promoter methylation analysis | ||
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood; Bone marrow | Blood borne tumours |
| Cytology samples; Formalin-fixed paraffin-embedded (FFPE) tissues | Solid tumours | |
| Formalin-fixed paraffin-embedded (FFPE) tissues | Solid tumours | |
| Molecular genetics - RNA extraction | Blood; Bone marrow; Formalin-fixed paraffin-embedded (FFPE) tissues | Viable RNA |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences; FASTQ files; VCF files | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
NIPT
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Molecular genetics - Non-invasive prenatal (genetic) screening | Maternal blood | Aneuploidy for chromosomes X and Y; Chromosome copy number analysis; Jacobs syndrome (XYY); Klinefelter syndrome (XXY); Rare autosome aneuploidy and segmental genomic imbalances; Trisomy 13, trisomy 18, trisomy 21; Trisomy X; Turners syndrome (SCA:XO) |
Toxicology Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Urine | 11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); 6-Monoacetylmorphine; 6β-Naltrexol; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Amitriptyline; Aripiprazole; Benzoylecgonine (ecgonine benzoate); Chlorpromazine; Citalopram; Clomipramine; Codeine; Desmethyl venlafaxine; Dextromethorphan; Dothiepin (dosulepin); Doxepin; Fentanyl; Fluvoxamine; Haloperidol; Hydrocodone; Hydromorphone; Imipramine; Lorazepam; Lysergic acid diethylamide (LSD, lysergide); Meperidine (pethidine); Methadone; Methamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Methylphenidate; Mirtazapine; Moclobemide; Morphine; Nordiazepam; Norketamine; Norquetiapine; Nortriptyline; Olanzapine; Oxazepam; Oxycodone; Oxymorphone; Paroxetine; Phencyclidine; Phentermine; Pholcodine; Pregabalin; Promethazine; Propoxyphene; Pseudoephedrine (PSE); Quetiapine; Ranitidine; Risperidone; Sertraline; Tapentadol; Temazepam; Thioridazine; Tramadol; Trifluoperazine; Trimipramine; Venlafaxine; Ziprasidone; Zolpidem; Zopiclone; α-Hydroxyalprazolam |
| Synthetic cannabis | ||
| 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); Buprenorphine; Fentanyl; Ketamine; Lysergic acid diethylamide (LSD, lysergide); Methadone; Methadone metabolites; Oxycodone; Phencyclidine; Propoxyphene; Tramadol | ||
| Alcohol; Barbiturates; Buprenorphine; Methadone metabolites; Oxycodone; Phencyclidine; Propoxyphene | ||
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | 6-Mercaptopurine; 6-Thioguanine |
| Chemical pathology - Quantitation of vitamin B markers | Serum | Methylmalonic acid (MMA) |
ISO 15189 (2022)
Legal
Medicare expiry date
23 Jul 2026
Last Activity Date
21 Mar 2024
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, section 2 Specimen collection, storage, handling and dispatch | Urine | Colour; Creatinine; Temperature; pH |
| Medico legal drug testing AS/NZS 4308:2008, section 3 General laboratory requirements | Urine | General laboratory requirements as described in AS/NZS 4308 |
| Medico legal drug testing AS/NZS 4308:2008, section 4 Laboratory screening procedures | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, section 5 Laboratory confirmatory procedures | Urine | 11-nor-9-carboxy-Δ9-Tetrahydrocannabinol; 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); 3,4-Methylenedioxyamphetamine (MDA); 3,4-Methylenedioxymethamphetamine (MDMA); 6-Monoacetylmorphine; 7-OH Quetiapine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Benzylpiperazine (BZP, 1-benzylpiperazine); Buprenorphine; Codeine; Codeine-6-glucuronide (codeine-6-β-D-glucuronide); Cortisol; Cortisone; Desmethyl venlafaxine; Diazepam; Dihydrocodeine (6α-hydrocodol); Ephedrine; Fentanyl; Gabapentin; Hydrocodone; Hydromorphone; Ketamine; Lorazepam; Lysergic acid diethylamide (LSD, lysergide); Meperidine (pethidine); Methadone; Methaqualone; Methylamphetamine; Methylphenidate; Morphine; Morphine-3-glucuronide (morphine-3-β-D-glucuronide); Morphine-6-glucuronide (morphine-6-β-D-glucuronide); Naloxone; Norbuprenorphine; Nordiazepam; Norfentanyl; Norketamine; Norquetiapine; Norsertraline; O-Desmethyltramadol; Oxazepam; Oxycodone; Oxymorphone; Phencyclidine; Phentermine; Pholcodine; Pregabalin; Propoxyphene; Pseudoephedrine (PSE); Quetiapine; Sertraline; Temazepam; Testosterone; Thebaine; Tramadol; Venlafaxine; Zaleplon; Zolpidem; α-Hydroxyalprazolam |
| (±)-3,4-Dimethylmethcathinone; (±)-3-Bromomethcathinone; (±)-Cathinone; (±)-Methcathinone; 25B-NBOMe (2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine); 25C-NBOMe (2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine); 3,4-Methylenedioxymethcathinone; 3,4-Methylenedioxypyrovalerone (MDPV); 3,4-methylenedioxy-N-ethylcathinone; 4-Fluoromethcathinone; 4-Methylephedrine; 4’-Methoxymethcathinone; 4’-Methylethcathinone; 4’-Methylmethcathinone; N-methyl-1,3-benzodioxolylbutanamine; para-Methoxyamphetamine; α-Pyrrolidinopropiophenone; α-Pyrrolidinovalerophenone (PVP); α-methylamino-valerophenone; β-keto-N-methylbenzodioxolylbutanamine | ||
| (S)-Zearalanone; 17α-Dimethyl-5β-Androstane-3α; 17α-Methyltestosterone; 17α-Trenbolone (epitrenbolone); 17β-diol Androstenedione; 19-Norandrosterone (19-NA); 1α-Methyl-5α-androstan-3α-ol-17-one; 4-Hydroxytestosterone; 5β-Androst-1-en-17β-ol-3-one 7α; Clenbuterol; Cortisol; Danazol; Dromostanolone enanthate; Drostanolone; Drostanolone propionate; Epitestosterone; Gestrinone; Mesterolone; Methandienone; Methasterone; Nandrolone; Oxandrolone; Stanozolol; Testosterone; Trenbolone; Trenbolone acetate; α-Zearalenol; α-Zeranol Boldenone; β-Zeranol | ||
| 11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; 6-Acetylmorphine; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Amphetamines; Benzoylecgonine (ecgonine benzoate); Benzylpiperazine (BZP, 1-benzylpiperazine); Codeine; Codeine-6-glucuronide (codeine-6-β-D-glucuronide); Diazepam; Ecgonine methyl ester; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Morphine-3-glucuronide (morphine-3-β-D-glucuronide); Morphine-6-glucuronide (morphine-6-β-D-glucuronide); Nordiazepam; Oxazepam; Phentermine; Pseudoephedrine (PSE); Temazepam; α-Hydroxyalprazolam | ||
| Medico legal drug testing AS/NZS 4760, appendix B Additional testing | Oral fluid | Alprazolam; Benzodiazepines; Buprenorphine; Clonazepam; Diazepam; Ecgonine methyl ester; Fentanyl; Flunitrazepam; Ketamine; Lysergic acid diethylamide (LSD, lysergide); Methadone; Nordiazepam; O-Desmethylvenalafaxine; Oxazepam; Phencyclidine; Phentermine; Pregabalin; Propoxyphene; Pseudoephedrine (PSE); Quetiapine; Sertraline; Temazepam; Venlafaxine and metabolites |
| Medico legal drug testing AS/NZS 4760, section 2 Collection, storage, handling and dispatch | Oral fluid | Handling and dispatch; Sample collection and storage |
| Medico legal drug testing AS/NZS 4760, section 4 Laboratory screen testing | Oral fluid | 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
| Medico legal drug testing AS/NZS 4760, section 5 Laboratory confirmatory procedures | Oral fluid | 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
1964
Site No.
23038
Print date
08 Oct 2024
END OF SCOPE